arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Stereotaxis, Inc.

STXS
$1.42 ▲ +0.06 (+4.41%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Stereotaxis, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $140.4M
Dividend Yield
Revenue Growth -15.8%
Op. Margin -95.1%
ROIC -32.9%
FCF / Share $-0.03
Trailing P/E
Price / Book 9.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.29M
↓ -15.8%
Net Income Profit after all expenses
$-5.86M
↓ -0.7%
Operating Margin Operating profit as % of sales
-95.1%
↓ -45.4% 4th
FCF / Share Free cash flow per share
$-0.03
↓ -71.7%
Long-Term Debt Long-term obligations
$243.62K
↓ -75.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
4
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters